Organigram Global (NASDAQ:OGI – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.
Profitability
This table compares Organigram Global and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organigram Global | 28.14% | -13.39% | -8.67% |
| InspireMD | -413.96% | -69.42% | -57.68% |
Earnings and Valuation
This table compares Organigram Global and InspireMD”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organigram Global | $309.18 million | 0.42 | -$17.70 million | $0.46 | 2.01 |
| InspireMD | $10.84 million | 1.95 | -$19.92 million | ($0.64) | -0.71 |
Organigram Global has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Comparatively, 25.0% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Organigram Global has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Organigram Global and InspireMD, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organigram Global | 1 | 0 | 2 | 0 | 2.33 |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
InspireMD has a consensus target price of $4.50, indicating a potential upside of 888.58%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Organigram Global.
Summary
Organigram Global beats InspireMD on 8 of the 14 factors compared between the two stocks.
About Organigram Global
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for Organigram Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram Global and related companies with MarketBeat.com's FREE daily email newsletter.
